Cargando…

Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma

BACKGROUND: Diffuse large B cell lymphoma (DLBCL) is the most common form of lymphoma. Although durable remissions can be achieved in more than half of these patients, DLBCL remains a significant clinical challenge, with approximately 30% of patients not being cured. BCR-associated kinases (SYK, BTK...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Yizi, Li, Jiao, Ding, Ning, Wang, Xiaogan, Deng, Lijuan, Xie, Yan, Ying, Zhitao, Liu, Weiping, Ping, Lingyan, Zhang, Chen, Song, Yuqin, Zhu, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379963/ https://www.ncbi.nlm.nih.gov/pubmed/30777096 http://dx.doi.org/10.1186/s13046-019-1076-4

Ejemplares similares

TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP
por: Liu, Yalu, et al.
Publicado: (2017)

EP300 single nucleotide polymorphism rs20551 correlates with prolonged overall survival in diffuse large B cell lymphoma patients treated with R-CHOP
por: Li, Jiao, et al.
Publicado: (2017)

Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma
por: Fu, Zhiying, et al.
Publicado: (2014)

Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment
por: Zheng, Xiaohui, et al.
Publicado: (2014)

ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma
por: Liu, Yalu, et al.
Publicado: (2019)

The Synergistic Anti-Tumor Activity of EZH2 Inhibitor SHR2554 and HDAC Inhibitor Chidamide through ORC1 Reduction of DNA Replication Process in Diffuse Large B Cell Lymphoma
por: Wang, Xing, et al.
Publicado: (2021)

Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs
por: Gelardi, T, et al.
Publicado: (2008)

Cerebrospinal Fluid Proteins Identification Facilitates the Differential Diagnosis of Central Nervous System Diffuse Large B Cell Lymphoma
por: Zheng, Wen, et al.
Publicado: (2017)

Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin
por: Deng, Lijuan, et al.
Publicado: (2015)

Ibrutinib in primary central nervous system diffuse large B-cell lymphoma
por: T Low, Justin, et al.
Publicado: (2020)

Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography using Deauville criteria in diffuse large B cell lymphoma treated with autologous hematopoietic stem cell transplantation
por: Ying, Zhitao, et al.
Publicado: (2019)

Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules
por: Shimokawa, T, et al.
Publicado: (2012)

Severe Lymphocytosis in a Case of Diffuse Large B-Cell Lymphoma Treated by Ibrutinib
por: Paydaş, Semra, et al.
Publicado: (2021)

Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab
por: Hu, Yunfei, et al.
Publicado: (2014)

Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules
por: Körner, A, et al.
Publicado: (2010)

PDGFD induces ibrutinib resistance of diffuse large B-cell lymphoma through activation of EGFR
por: Jin, Jia, et al.
Publicado: (2020)

Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
por: Ren, Liangliang, et al.
Publicado: (2021)

The Serum- and Glucocorticoid-Inducible Kinase 1 (SGK1) as a Novel Therapeutic Target in Mantle Cell Lymphoma
por: Li, Jiao, et al.
Publicado: (2022)

Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma
por: Li, Jiazheng, et al.
Publicado: (2021)

Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma
por: Herrera, Alex F., et al.
Publicado: (2019)

Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation
por: Hodkinson, Brendan P., et al.
Publicado: (2020)

Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma
por: Yu, Hui, et al.
Publicado: (2021)

Combination Treatments with the PKC Inhibitor, Enzastaurin, Enhance the Cytotoxicity of the Anti-Mesothelin Immunotoxin, SS1P
por: Mattoo, Abid R., et al.
Publicado: (2013)

Ibrutinib in B-cell lymphoma: single fighter might be enough?
por: Xue, Chao, et al.
Publicado: (2020)

Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma
por: Tian, Chen, et al.
Publicado: (2020)

Systemic Aspergillosis: Radiological Findings in a Case With Diffuse Large B Cell Lymphoma Treated by Ibrutinib
por: Pehlivan, Umur Anil, et al.
Publicado: (2021)

The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma
por: Shi, Cunzhen, et al.
Publicado: (2018)

Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells
por: Tekle, C, et al.
Publicado: (2008)

The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages
por: Ping, Lingyan, et al.
Publicado: (2017)

Inhibition of Glycogen Synthase Kinase 3 (GSK3) Increases the Cytotoxicity of Enzastaurin
por: Rovedo, Mark, et al.
Publicado: (2011)

The PKC-β selective inhibitor, Enzastaurin, impairs memory in middle-aged rats
por: Willeman, Mari N., et al.
Publicado: (2018)

A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type
por: Lin, Ningjing, et al.
Publicado: (2013)

Outcomes of dose-adjusted Berlin–Frankfurt–Münster-90 regimen without radiotherapy in adolescents and adults with T cell lymphoblastic lymphoma
por: Xie, Yan, et al.
Publicado: (2015)

A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphoma
por: Li, Xueying, et al.
Publicado: (2016)

The Protein Kinase C Inhibitor Enzastaurin Exhibits Antitumor Activity against Uveal Melanoma
por: Wu, Xinqi, et al.
Publicado: (2012)

Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics
por: Nwankwo, Nwabundo, et al.
Publicado: (2012)

Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas
por: Wu, Meng, et al.
Publicado: (2018)

Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy
por: Fox, Lucy C., et al.
Publicado: (2018)

Identification of an individualized RNA binding protein‐based prognostic signature for diffuse large B‐cell lymphoma
por: Xie, Yongzhi, et al.
Publicado: (2021)

Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin’s Lymphoma
por: Ying, Zhitao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_v6rbq7fg5bakl1maapbc8oqfv3